ENDRA Life Sciences to Participate in Two March Investor Conferences

ENDRA Life Sciences Inc. (NASDAQ: NDRA), a pioneer of Thermo Acoustic Enhanced UltraSound (TAEUS®), announces that management will participate in two investor conferences during March:

• 34th Annual ROTH Conference, March 13-15, 2022 at The Ritz-Carlton Laguna Niguel. Management will be available for one-on-one meetings on Monday, March 14, 2022. In addition, a pre-recorded company presentation will be available in the Investors section of ENDRA’s website here.

• Oppenheimer’s 32nd Annual Healthcare Conference, March 15-16, 2022. Management will deliver a company presentation on Tuesday, March 15th at 2:40 p.m. ET and will be available for one-on-one virtual meetings.

About ENDRA Life Sciences Inc.

ENDRA Life Sciences is the pioneer of Thermo Acoustic Enhanced UltraSound (TAEUS®), a ground-breaking technology being developed to visualize tissue like MRI, but at 1/50th the cost and at the point of patient care. TAEUS® is designed to work in concert with 400,000 cart-based ultrasound systems in use globally today. TAEUS® is initially focused on the measurement of fat in the liver as a means to assess and monitor Non-Alcoholic Fatty Liver Disease (NAFLD) and inflammation (NASH), chronic liver conditions that affect over one billion people globally, and for which there are no practical diagnostic tools. Beyond the liver, ENDRA is exploring several other clinical applications of TAEUS®, including visualization of tissue temperature during energy-based surgical procedures. For more information, please visit www.endrainc.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20220303005114/en/

Company Contact: Irina Pestrikova Senior Director, Finance [e-mail] www.endrainc.com

Investor Relations Contact: Yvonne Briggs LHA Investor Relations [phone] [e-mail]